Secondary Scrotal Necrosis to Terlipressin Treatment in a Patient with Hepatorenal Syndrome

Year 2019, Volume: 6 Issue: 3, 163 - 165, 31.12.2019

Volkan Karakuş , Dilek Ersil Soysal

Abstract

Hepatorenal syndrome
is a reversible acute renal impairment that occurs in patients with advanced
liver cirrhosis or fulminant hepatic failure. Terlipressin is a synthetic
long-acting analogue of vasopressin that is used in the treatment of
hepatorenal syndrome. Ischemic adverse events of the treatment with terlipressin
have been reported. We present a rare complication of terlipressin usage,
ischemic skin necrosis of the scrotum, in a patient with advanced liver
cirrhosis and hepatorenal syndrome.

Keywords

Glypressin, Hepatorenal Syndrome, Liver Cirrhosis, Vascular

Hepatorenal Sendromlu Bir Hastada Terlipressin Tedavisine İkincil Skrotal Nekroz

Abstract

Hepatorenal sendrom, ilerlemiş karaciğer sirozu
veya fulminan karaciğer yetmezliği olan hastalarda ortaya çıkan, tersinir bir
akut böbrek yetmezliğidir. Terlipressin, hepatorenal sendromun tedavisinde
kullanılan sentetik uzun süre etkili bir vazopressin analoğudur. Terlipressin
ile tedavinin iskemik advers olayları bildirilmiştir. Karaciğer sirozu ve
hepatorenal sendromlu bir hastada terlipressin kullanımının nadir görülen bir
komplikasyonunu, skrotumun iskemik cilt nekrozunu sunuyoruz.

Keywords

Glipressin, Hepatorenal Sendrom, Karaciğer Sirozu, Vasküler

References

• 1. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database of Systematic Reviews 2006, Issue 4. Art No.: CD005162. DOI: 10.1002/14651858.CD00162.pub2. Available from: http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/ CD005162/pdf_fs.html
• 2. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923–30.
• 3. Krag A, Borup T, Moller S, Bendtsen F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther. 2008; 25(11):1105-40.
• 4. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, non-randomized study. Hepatology 2002;36(4):941–8.
• 5. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006;24:935–44.
• 6. Ginés P, Torre A, Terra C, Guevara M. Review article: pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther. 2004;20(3):57–62.
• 7. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41(6):1282-9.
• 8. Megarbane H, Barete S, Khosrotehrani K, et al. Two observations raising questions about risk factors of cutaneous necrosis induced by terlipressin (Glypressin). Dermatology. 2009;218(4):334-7.
• 9. Vaccaro F, Giorgi A, Riggio O, De Santis A, Laviano A, Rossi-Fanelli F. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report. Dig Liver Dis. 2003;35:503-6.
• 10. Oh JE, Ha JS, Cho DH, Yu GJ, Shim SG. A case of ischemic skin necrosis after glypressin therapy in liver cirrhosis. Korean J Gastroenterol. 2008; 51(6) :381-4.